Related Experiment Videos
Interleukin-17 in acute myeloid leukemia
T Wróbel1, G Mazur, Bozena Jazwiec
1Department of Haematology, Wroclaw Medical University, Wroclaw, Poland. wrobelt@hemat.am.wroc.pl
Journal of Cellular and Molecular Medicine
|February 3, 2004
Summary
Interleukin-17 (IL-17) does not appear elevated in acute myeloid leukemia (AML) patients, suggesting CD4 T cells do not drive angiogenesis in this cancer. This study is the first to examine IL-17 levels in acute leukemias.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Angiogenesis is crucial in hematological malignancies like acute myeloid leukemia (AML).
- Human interleukin-17 (IL-17), a cytokine from CD4 T cells, may mediate T cell-driven angiogenesis.
- The role of IL-17 in pathological angiogenesis remains unclear.
Purpose of the Study:
- To investigate plasma levels of IL-17 in adult patients diagnosed with AML.
- To determine if IL-17 is associated with angiogenesis in AML.
Main Methods:
- Plasma samples from 68 adult AML patients before chemotherapy were analyzed using ELISA.
- IL-17 levels were also measured in 20 patients post-complete remission (CR).
- Ten samples from healthy volunteers served as controls.
Main Results:
- Serum IL-17 levels were not found to be elevated in AML patients compared to controls.
- No significant difference in IL-17 levels was observed between pre-chemotherapy and CR states.
Conclusions:
- The findings suggest that angiogenesis in AML is not primarily mediated by CD4 T cells via IL-17.
- This study provides the first report on IL-17 serum levels in acute leukemias.
- Further research is ongoing to evaluate IL-17 in other hematological malignancies.